ss-31 clinical trials 18 clinical trials of SS-31 in humans - SS-31peptide bodybuilding longer administration of SS-31 may be needed in clinical trials SS-31 Clinical Trials: Exploring a Powerful Mitochondria-Targeting Peptide

SS-31dosing protocol The landscape of therapeutic development is constantly evolving, with a growing focus on targeting the root causes of various diseases.作者：S Russo·2022·被引用次数：28—Our results indicate thatSS-31have beneficial effects on improving cardiac mitochondrial dysfunction in a BTHS animal model. Among the promising avenues, mitochondria-targeted therapies have emerged as a significant area of researchThis is a multicenter phase 3 randomized, double-blind, parallel-group, placebo-controlledtrialto evaluate the safety and efficacy of daily subcutaneous .... SS-31, a mitochondria-targeted tetrapeptide, also known by its investigational drug name Elamipretide (and formerly Bendavia), stands at the forefront of this movement. This article delves into the ongoing and completed SS-31 clinical trials, exploring its mechanism of action, the diseases it aims to treat, and the findings that underscore its potential.

Understanding SS-31: A Mitochondria-Focused Approach

SS-31 is a small molecule designed to selectively accumulate within mitochondria. Its primary mechanism involves interacting with cardiolipin, a crucial phospholipid found in the inner mitochondrial membrane. This interaction helps to restore mitochondrial function, primarily by preserving mitochondrial membrane potential, reducing reactive oxygen species (ROS) production, and enhancing ATP synthesis. This targeted approach differentiates SS-31 from broader antioxidants, allowing for more specific and potent effects on cellular energy production and oxidative stress management within the powerhouses of our cells. Research has indicated that SS-31 treatment reduces Aβ production and maintains mitochondrial dynamics, suggesting a role in neurodegenerative processes as well. Furthermore, SS-31 peptide has been shown to improve mitochondrial function and is effective in various clinical trials.

The Scope of SS-31 Clinical Trials

The potential of SS-31 is being evaluated across a wide spectrum of conditions, with current studies on SS-31 predominantly focusing on diseases characterized by mitochondrial dysfunction作者：X Kuang·2017·被引用次数：47—Intratympanic dexamethasone is now being evaluated in phase IVclinical trialfor the treatment of cisplatin-induced ototoxicity (https://clinicaltrials.gov).. While clinical trials have further highlighted its potential in conditions like heart failure and primary mitochondrial myopathy, its applications extend far beyond.

Mitochondrial Diseases and Related Conditions

A significant portion of SS-31 clinical trials are dedicated to rare genetic mitochondrial disorders. Elamipretide has shown promise in conditions such as Barth syndrome, a rare X-linked disorder that affects primarily males, leading to muscle weakness, fatigue, and heart problemsClinical trials with SS-31 have reported promising results in age-related conditionsincluding heart failure, muscle weakness, chronic kidney disease and .... Early clinical trials in heart failure and primary mitochondrial myopathy have been conducted, with some yielding mixed results. However, SS-31 is also currently under clinical trials for various other mitochondrial disorders, including mitochondrial genetic diseases and primary mitochondrial myopathy. The FDA has approved therapies for certain mitochondrial conditions, highlighting the importance of this field. Some studies, like the one involving elamipretide in Barth syndrome, indicate sustained long-term tolerability and efficacy, with improvements in functional assessments and cardiac functionElamipretide – Knowledge and References.

Cardiovascular and Renal Applications

The beneficial effects of SS-31 on cardiac function have been a central theme in many studies. Research indicates that SS-31 treatment ameliorates cardiac mitochondrial dysfunction, and a few years ago, SS-31 was tested in an American clinical trial as a potential therapy for Barth syndrome patients. Beyond the heart, SS31 has been shown to be effective for acute kidney injury and ischemia-reperfusion-derived organ damage.Mitochondrial protein interaction landscape of SS-31 SS-31 clinical trials have included investigations into its role in improving kidney health, with some research suggesting it can ameliorate kidney damage.

Neurological and Age-Related Conditions

The neuroprotective potential of SS-31 is also being explored. Oxidative stress and mitochondrial dysfunction are implicated in age-related cognitive decline and neurodegenerative diseasesSS-31 Peptide | Benefits, Safety & Buying Advice [2026]. Early research has suggested that SS-31 treatment reduces Aβ production, a hallmark of Alzheimer's diseaseOngoing clinical trials with elamipretide.. Furthermore, future clinical trials with SS-31 in elderly patients are feasible, which would allow for its potential in improving cerebro-microvascular and age-related conditions.Application research of novel peptide mitochondrial ... Clinical trials with SS-31 have reported promising results in age-related conditions including heart failure and muscle weakness作者：Q Yang·2022·被引用次数：9—SS31 treatment effectively enhanced the recovery of skeletal muscle function, alleviated skeletal muscle injury and suppressed mitochondrial ROS production in ....

Other Investigational Areas

The versatility of SS-31 extends to other conditionsMitochondria-targeted small molecule SS31: a potential .... For instance, SS31 treatment effectively enhanced the recovery of skeletal muscle function, alleviating skeletal muscle injury.作者：PH Reddy·2017·被引用次数：153—Our findings indicate thatSS31 treatment reduces Aβ production, reduces mitochondrial dysfunction, maintains mitochondrial dynamics and enhances mitochondrial ... There's also interest in its role in conditions like age-related macular degeneration, with some clinical trials investigating its application in this area. SS-31 is also the subject of numerous active clinical trials concerning an array of health conditions, such as macular degeneration.

Evolving Research and Future Directions

The journey of SS-31 from a laboratory discovery to a potential therapeutic agent involves rigorous scientific investigation. Over 18 clinical trials of SS-31 in humans have been systematically analyzed, offering a comprehensive overview of both successful and unsuccessful outcomes. While some clinical trials in heart failure and primary mitochondrial myopathy have failed, the broader landscape of research remains active.Application research of novel peptide mitochondrial ...

It is important to note that no clinical trials are ongoing on this interesting molecule in certain contexts, but this can change as research progresses. There are also discussions around SS-31 dosage and SS-31 dosing protocol, as understanding the optimal administration is critical for efficacy. Some studies suggest that longer administration of SS-31 may be needed to achieve full beneficial effects.2025年9月25日—The FDA has approved a first-of-its-kind mitochondrial therapy in the U.S. for the treatment of Barth syndrome, a rare condition that causes ...

Several large-scale randomized controlled trials for various mitochondrial diseases are envisioned, alongside dose optimization studies for different clinical conditions and patient populations. The development of SS-31 peptide continues to be a significant area of focus, with ongoing efforts to unlock its full therapeutic potential. The peptide itself has demonstrated SS-31 peptide benefits in numerous preclinical and clinical settings.

In conclusion, the SS-31 clinical trials represent a significant advancement in the pursuit of novel treatments for a range of debilitating conditions. By targeting the fundamental role of mitochondria in cellular health, SS-31 (Elamipretide) holds substantial promise for improving patient outcomes across diverse disease areas.